UPDATE: Jefferies Raises PT on Celgene Corporation from $75 to $80

Jefferies reiterated a Buy rating on Celgene Corporation CELG and raised its price target from $75 to $80. Jefferies commented, “CELG beat 2Q estimates for Revlimid sales and increased 2012 EPS guidance. We remain confident in the long-term prospects for Revlimid driven by maintenance duration and new indications. We are raising our price target from $75 to $80.” Celgene Corporation closed at $67.49 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!